About the Editors

ANDREW J. FLETCHER, MB, BChir, (Cantab), MS (Columbia), FFPM, DipPharmMedRCP, is Senior Assistant Editor of The Merck Manuals, Merck & Co. Inc. and Adjunct Professor of Pharmaceutical Health Care at Temple University School of Pharmacy. He graduated from Cambridge University and St. Bartholomew's Hospital, London, briefly trained in Neurosurgery, joined CIBA-GEIGY in the UK as Medical Advisor, then European Medical Director, for Syntex, then joined Merck, first in the international division after graduating in business from Columbia University, New York City, he joined the Merck Manual as Assistant Editor. He teaches pharmaceutical medicine, bioethics, and medical and scientific writing at Temple University's School of Pharmacy. He is a founder member and ex-trustee of the American Academy of Pharmaceutical Physicians.

LIONEL D. EDWARDS, MB, BS, LRCP, MRCS, Dip RCOG and FFPM., is President of Pharma Pro Plus Inc., a drug development consulting company and Director Medical Affairs Novartis USA. Previously, he was Vice President of Clinical Research at Bio-Technology Pharmaceutical Corporation, a small Biotech firm making a profit with operations in the US and International marketplaces. Prior to this he worked at Noven, Inc., a small Skin Patch Technology firm with large internationally licensed partners—Ciba and Rhone Poulenc Rorer. He was Assistant Vice-President, International Clinical Research at Hoffman-La Roche, and Senior Director of Schering-Plough International Research, and Director of US Domestic Gastrointestinal, Hormonal and OTC Research Departments. Dr. Edwards has been involved in all aspects of clinical trials over the years on many different research drug devices in 10 therapeutic areas.

He served as Chairman of the PMA Special Population committee for 5 years, also he was on the Institute of Medicine Committee for Research in Women, sponsored by the NIH. He served on the efficacy subcommittee Topic 5 (Acceptability of Foreign Clinical Data) of the International Committee on Harmonization (ICH).

He is a Fellow of the Faculty of Pharmaceutical Medicine and an Adjunct Professor at Temple University Graduate School of Pharmacology. He has taught 'Drug Development' for PERI for over ten years and is on the teaching faculty of the National Association of Physicians. He is a founder member of the American Academy of Pharmaceutical Physicians.

ANTHONY ('Tony') W. FOX, BSc, MBBS, FFPM, MD (Lond), DipPharmMedRCP, CBiol, FIBiol, is President of EBD Group, San Diego. From The Royal London Hospital, after general clinical training he was Rotary International Fellow at Emory University (Atlanta), and CIBA-Geigy Fellow at Harvard. Industrial positions at Procter and Gamble and Glaxo came next. He was then Vice-President of a small pharmaceutical company. Among many societies, Tony is Charter Member, Trustee, and Education VP of the American Academy of Pharmaceutical Physicians. Publications span several areas of pharmaceutical medicine, e.g., regulation, pharmacology, clinical trials, pharmacovigilance, analgesics, migraine, genotoxicology, and metabolism. He has four patents, and five journals use his reviews.

PETER D. STONIER, BA, BSc, PhD, MBChB, MRCPsych, FRCP, FRCPE, FFPM has 24 years experience in pharmaceutical medicine. He was Medical and Board Director of the UK Hoechst Group of companies until he became a consultant in 2000. He is immediate past-President of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians UK. Formerly he was President of the International Federation of Associations of Pharmaceutical Physicians and Chairman of the British Association of Pharmaceutical Physicians. He is Visiting Professor in pharmaceutical medicine at Kings College, London and at the University of Surrey, which under his direction introduced the first MSc degree in Pharmaceutical Medicine in 1993. His publications include edited works in human psy-chopharmacology, clinical research, medical marketing and careers in the pharmaceutical industry. He is a graduate of Manchester Medical School, qualifying in 1974, following a BSc degree in physiology and a PhD in protein chemistry.

0 0

Post a comment